Cargando…

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapa, Constantin, Kircher, Malte, Hänscheid, Heribert, Schirbel, Andreas, Grigoleit, Götz Ulrich, Klinker, Erdwine, Böck, Markus, Samnick, Samuel, Pelzer, Theo, Buck, Andreas K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771082/ https://www.ncbi.nlm.nih.gov/pubmed/29344295 http://dx.doi.org/10.7150/thno.22161

Ejemplares similares

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Kreissl, Michael C, et al.
Publicado: (2012)

Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI
por: Lapa, Constantin, et al.
Publicado: (2016)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

CXCR4-targeted theranostics in oncology
por: Buck, Andreas K., et al.
Publicado: (2022)

The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT
por: Zhou, Xiang, et al.
Publicado: (2020)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

(68)Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with(18)F-FDG, calcium burden and risk factors
por: Li, Xiang, et al.
Publicado: (2012)

Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation
por: Kircher, Malte, et al.
Publicado: (2017)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology
por: Lückerath, Katharina, et al.
Publicado: (2013)

(18)FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
por: Lapa, Constantin, et al.
Publicado: (2014)

Sarcoid-like reactions: a potential pitfall in oncologic imaging
por: Gebrekidan, Selamawit, et al.
Publicado: (2020)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

[(18)F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?
por: Kertels, Olivia, et al.
Publicado: (2023)

(11)C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma
por: Lückerath, Katharina, et al.
Publicado: (2015)

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
por: Şen, Feyza, et al.
Publicado: (2023)

Radionuclide Imaging of Neurohormonal System of the Heart
por: Chen, Xinyu, et al.
Publicado: (2015)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial
por: Isberner, Nora, et al.
Publicado: (2021)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?
por: Lapa, Constantin, et al.
Publicado: (2015)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients
por: Gerner, Bettina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_na5tj6cqokfrdivhrp13rar5o2